David Meek only started work as CEO of France’s mid-sized pharmaceutical company, Ipsen, a couple of weeks ago, but he has already seen his new company gain a positive opinion from Europe’s CHMP for a new cancer product, and the presentation of positive earnings results for the second quarter of 2016.
“I couldn’t ask for a better first 10 days,” he told analysts during a July 28 review of the company’s...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
